N/A N=82 TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions
Peripheral Arterial Disease
Primary: Number of Participants Free From Target Lesion Revascularization (TLR) — 52 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=86 Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels
Coronary Artery Disease
Primary: In Stent Mean Cross-sectional Area of Neo-intimal Tissue Coverage — 1.381; 0.949 mm^2
Phase 4 N=20 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging
Peripheral Artery Disease · Vascular Disease · Critical Limb Ischemia
Primary: Change in Percent Wall Volume (PWV) — 12.3; 3.9 Percent Wall Volume — p=0.22
N/A N=29 JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
Restenosis · Peripheral Vascular Disease
Primary: Acute Procedural Success — 29 limbs
N/A N=499 STELLAREX: ILLUMENATE Global and In-Stent Restenosis (ISR)
Peripheral Arterial Disease
Primary: Percentage of Participants With Freedom From Device and Procedure-related Death and Freedom From Target Limb Major Amputation and Clinically-driven Target Lesion…
Phase 3 N=100 NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions
Coronary Artery Disease
Primary: Percentage of Participants Who Achieved Procedure Success From Post-procedure to Hospital Discharge — 97 Percentage of Participants
N/A N=51 CVT-ISR First in Human Trial for Coronary In-Stent Restenosis
In-stent Restenosis
Primary: The Primary Safety Endpoint for the CVT-ISR Study: Freedom From Target Lesion Failure (TLF) Rate — 4; 1; 0; 3 Participants
Phase 3 N=100 Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions
Coronary Artery Disease
Primary: Percentage of Participants Who Experienced In-lesion Restenosis as Measured by Quantitative Coronary Angiography (QCA) at 6 Months Post-procedure — 16.9 Percentage of…
Phase 2 N=41 PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis
In-Stent Restenosis
Primary: Percent Diameter Stenosis (%DS) in the Analysis Segment — 36.0 Percentage stenosis of vessel diameter
N/A N=100 NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions
Atherosclerosis · Coronary Artery Disease
Primary: Technical Success Rate — 99.2 percentage of lesions
N/A N=299 SuperNOVA Clinical Stenting Trial
Atherosclerosis of Native Arteries of the Extremities, Unspecified
Primary: Primary Safety Endpoint and Components — 85.8; 14.2; 0.0; 0.4 percentage of participants
N/A N=222 EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
Coronary Artery Disease (CAD) · Chronic Total Occlusion (CTO)
Primary: Number of Participants With Stent-related: Major Adverse Cardiac Events (MACE) (Per ITT Set) — 39 Participants
N/A N=214 Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques
Stable Angina
Primary: Percentage of Participants With Major Adverse Cardiac Events(MACE) — 1.72; 6.86 percentage of participants
Phase 4 N=200 Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents
Coronary Heart Disease · Coronary Restenosis
Primary: Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions. — 5483; 7658.2 US dollars — p=<0.05
N/A N=65 RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries
Arterial Occlusive Diseases · Myocardial Ischemia · Cardiovascular Diseases
Primary: Target Lesion Failure(TLF) — 4.62 percentage of TLF
Phase 3 N=102 The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)
Coronary Artery Disease
Primary: Target Lesion Failure (TLF) — 3.2 percentage of participants — p=<0.0001
Phase 4 N=479 Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction
Myocardial Infarction
Primary: Device-oriented Composite Outcome — 12; 13 participants
N/A N=8 Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement
Coronary Artery Disease
Primary: Percent Stent Coverage — 1; 0; 3; 1 Participants
N/A N=275 FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis
Restenosis
Primary: Percentage of Participants With Access Circuit Primary Patency (ACPP) That is Superior for FLUENCY® PLUS Endovascular Stent Graft (Following Percutaneous Transluminal…
N/A N=82 Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
Femoral Artery Stenosis · Femoral Artery Occlusion · Restenosis
Primary: Percentage of Participants With Primary Patency at 1 Year — 67.0; 49.5 Percentage of Participants
N/A N=60 Rotational Atherectomy Combined With Cutting Balloon to Optimize Stent Expansion in Calcified Lesions
Coronary Artery Disease · Atherosclerosis
Primary: Minimum Stent Area After Percutaneous Coronary Intervention — 6.7; 6.9 mm^2
Phase 4 N=597 Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
Saphenous Vein Graft Atherosclerosis
Primary: Number of Participants With Target Vessel Failure (TVF), Defined as the Composite of Cardiac Death — 16; 17 Participants
Phase 2 N=101 LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis
Atherosclerosis · Vascular Disease · Arteriosclerosis
Primary: Angiographic Late Lumen Loss — 0.46; 1.09 mm — p=0.016
Phase 2 N=158 Revacept in Symptomatic Carotid Stenosis
Carotid Stenosis · Atherosclerosis · Stroke
Primary: New DWI Lesion(s) — 1.2; 1.0; 0.6 Number of new lesions
Phase 4 N=888 Clinical Investigation for Everolimus Drug Eluting Stent
Coronary Arterial Disease (CAD)
Primary: 888 Number of Participants With Major Adverse Cardiac Events (MACE) at 30 Days — 0 participants
Phase 2 N=12 Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
Coronary Restenosis
Primary: Phase I: Number of Participants With Dose-limiting Toxicities — 0; 0; 0; 0 participants
N/A N=94 The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels
Coronary Artery Disease
Primary: Target Lesion Failure (TLF) — 2.4 percentage of participants — p=<0.0001
N/A N=1,334 Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
Coronary Artery Disease · Atherosclerosis, Coronary · Myocardial Ischemia
Primary: Percentage of Participants With Target Lesion Failure (TLF) at 12 Months Post-Index Procedure by Bayesian Estimation — 6.32; 8.90 Percentage of participants
N/A N=93 AngioSculpt® Coronary Bifurcation Study
Coronary Artery Disease · Myocardial Ischemia
Primary: Procedural Success — 91.4 percentage of participants
N/A N=40 A New Surgical-restorative Approach to Treat Gingival Recessions Associated With Non-carious Cervical Lesions (NCCL)
Gingival Recession · Tooth Abrasion
Primary: Percentage of Defect Coverage — 15; 14 Gingival recessions